Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 36


Azithromycin induces anti-viral effects in cultured bronchial epithelial cells from COPD patients.

Menzel M, Akbarshahi H, Bjermer L, Uller L.

Sci Rep. 2016 Jun 28;6:28698. doi: 10.1038/srep28698.


The Belgian trial with azithromycin for acute COPD exacerbations requiring hospitalization: an investigator-initiated study protocol for a multicenter, randomized, double-blind, placebo-controlled trial.

Vermeersch K, Gabrovska M, Deslypere G, Demedts IK, Slabbynck H, Aumann J, Ninane V, Verleden GM, Troosters T, Bogaerts K, Brusselle GG, Janssens W.

Int J Chron Obstruct Pulmon Dis. 2016 Mar 31;11:687-96. doi: 10.2147/COPD.S95501. eCollection 2016.


Aerobic Bacteriological Study of Acute Exacerbations of Chronic Obstructive Pulmonary Disease.

Sharan H.

J Clin Diagn Res. 2015 Aug;9(8):DC10-2. doi: 10.7860/JCDR/2015/14515.6367. Epub 2015 Aug 1.


Self-reported alcohol intake and risk of acute exacerbations of chronic obstructive pulmonary disease: a prospective cohort study.

Wetherbee EE, Niewoehner DE, Sisson JH, Lindberg SM, Connett JE, Kunisaki KM.

Int J Chron Obstruct Pulmon Dis. 2015 Jul 20;10:1363-70. doi: 10.2147/COPD.S86572. eCollection 2015.


Effects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: a randomised controlled trial.

Brill SE, Law M, El-Emir E, Allinson JP, James P, Maddox V, Donaldson GC, McHugh TD, Cookson WO, Moffatt MF, Nazareth I, Hurst JR, Calverley PM, Sweeting MJ, Wedzicha JA.

Thorax. 2015 Oct;70(10):930-8. doi: 10.1136/thoraxjnl-2015-207194. Epub 2015 Jul 15.


Azithromycin inhibits IL-1 secretion and non-canonical inflammasome activation.

Gualdoni GA, Lingscheid T, Schmetterer KG, Hennig A, Steinberger P, Zlabinger GJ.

Sci Rep. 2015 Jul 8;5:12016. doi: 10.1038/srep12016.


Prophylactic use of macrolide antibiotics for the prevention of chronic obstructive pulmonary disease exacerbation: a meta-analysis.

Ni W, Shao X, Cai X, Wei C, Cui J, Wang R, Liu Y.

PLoS One. 2015 Mar 26;10(3):e0121257. doi: 10.1371/journal.pone.0121257. eCollection 2015.


Self-reported sleep quality and acute exacerbations of chronic obstructive pulmonary disease.

Geiger-Brown J, Lindberg S, Krachman S, McEvoy CE, Criner GJ, Connett JE, Albert RK, Scharf SM.

Int J Chron Obstruct Pulmon Dis. 2015 Feb 20;10:389-97. doi: 10.2147/COPD.S75840. eCollection 2015.


Relationship between azithromycin susceptibility and administration efficacy for nontypeable Haemophilus influenzae respiratory infection.

Euba B, Moleres J, Viadas C, Barberán M, Caballero L, Grilló MJ, Bengoechea JA, de-Torres JP, Liñares J, Leiva J, Garmendia J.

Antimicrob Agents Chemother. 2015 May;59(5):2700-12. doi: 10.1128/AAC.04447-14. Epub 2015 Feb 23.


Azithromycin attenuates cigarette smoke extract-induced oxidative stress injury in human alveolar epithelial cells.

Chen M, Yang T, Meng X, Sun T.

Mol Med Rep. 2015 May;11(5):3414-22. doi: 10.3892/mmr.2015.3226. Epub 2015 Jan 20.


The effect of azithromycin in adults with stable neutrophilic COPD: a double blind randomised, placebo controlled trial.

Simpson JL, Powell H, Baines KJ, Milne D, Coxson HO, Hansbro PM, Gibson PG.

PLoS One. 2014 Aug 22;9(8):e105609. doi: 10.1371/journal.pone.0105609. eCollection 2014.


The cardiovascular safety of azithromycin.

Juurlink DN.

CMAJ. 2014 Oct 21;186(15):1127-8. doi: 10.1503/cmaj.140572. Epub 2014 Aug 5. No abstract available.


Macrolide antibiotics for prevention of chronic obstructive pulmonary disease exacerbations: are we there yet?

Restrepo MI, Anzueto A.

Am J Respir Crit Care Med. 2014 Jul 1;190(1):1-2. doi: 10.1164/rccm.201406-1014ED. No abstract available.


Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy.

Han MK, Tayob N, Murray S, Dransfield MT, Washko G, Scanlon PD, Criner GJ, Casaburi R, Connett J, Lazarus SC, Albert R, Woodruff P, Martinez FJ.

Am J Respir Crit Care Med. 2014 Jun 15;189(12):1503-8. doi: 10.1164/rccm.201402-0207OC.


Nonparametric tests of treatment effect based on combined endpoints for mortality and recurrent events.

Tayob N, Murray S.

Biostatistics. 2015 Jan;16(1):73-83. doi: 10.1093/biostatistics/kxu013. Epub 2014 Apr 8.


Macrolide antibiotics and the risk of cardiac arrhythmias.

Albert RK, Schuller JL; COPD Clinical Research Network.

Am J Respir Crit Care Med. 2014 May 15;189(10):1173-80. doi: 10.1164/rccm.201402-0385CI. Review.


Impact of heterozygote CFTR mutations in COPD patients with chronic bronchitis.

Raju SV, Tate JH, Peacock SK, Fang P, Oster RA, Dransfield MT, Rowe SM.

Respir Res. 2014 Feb 11;15:18. doi: 10.1186/1465-9921-15-18.


Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations.

O'Reilly PJ, Jackson PL, Wells JM, Dransfield MT, Scanlon PD, Blalock JE.

BMJ Open. 2013 Dec 23;3(12):e004140. doi: 10.1136/bmjopen-2013-004140.


Effects of broad-spectrum antimycobacterial therapy on chronic pulmonary sarcoidosis.

Drake WP, Richmond BW, Oswald-Richter K, Yu C, Isom JM, Worrell JA, Shipley GR.

Sarcoidosis Vasc Diffuse Lung Dis. 2013 Nov 25;30(3):201-11.

Items per page

Supplemental Content

Loading ...
Support Center